CDC like kinase 1
Clk(1–4) are CDC2-like kinases with dual specificity, they can autophosphorylate at tyrosine residues and phosphorylate their substrates on serine/threonine residues. CLKs are mainly found in the cytoplasm and in the nucleus where they are implicated in alternative splicing control1. Inhibition of CLKs 1, 2 or 4 accelerates midbody resolution in normally segregating cells and correlates with premature abscission, chromatin breakage and generation of DNA damage in cytokinesis with trapped chromatin. CLK1 plays an important role in the regulation of RNA splicing through phosphorylation of members of the serine and arginine-rich (SR) family of splicing factors. CLK1 was shown to be a promising target involved in the Alzheimer’s disease and autophagy-related diseases2,3.
CLK1 kinase assay is run on mobility shift microfluidics platform (Caliper), which provides best in industry quality of data. We routinely run services associated with this kinase including: screening, profiling, dose-response studies and kinetic measurements. Please contact us for more information.
1. Petsalaki E, Zachos G. Clks 1, 2 and 4 prevent chromatin breakage by regulating the Aurora B-dependent abscission checkpoint. Nature communications. 2016;7.
2. Jain P, Karthikeyan C, Hari Narayana Moorthy NS, Kumar Waiker D, Kumar Jain A, Trivedi P. Human CDC2-like kinase 1 (CLK1): A novel target for Alzheimer’s disease. Current drug targets. 2014 May 1;15(5):539-50.
3. Sun QZ, Lin GF, Li LL, Jin XT, Huang LY, Zhang G, Yang W, Chen K, Xiang R, Chen C, Wei YQ. Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers. Journal of medicinal chemistry. 2017 Jul 17;60(14):6337-52.